Esperion Therapeutis.Inc. buy Maxi_Scalibusa
Start price
21.01.18
/
50%
€68.78
Target price
22.05.18
€208.81
Performance (%)
-49.25%
End price
22.05.18
€34.91
Summary
This prediction ended on 22.05.18 with a price of €34.91. Massive losses of -49.25% were the result for the BUY prediction by Maxi_Scalibusa. Maxi_Scalibusa has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 0.399% | 0.399% | 172.539% | 106.334% |
| iShares Core DAX® | -0,10 % | 0,54 % | 3,31 % | 53,02 % |
| iShares Nasdaq 100 | 0,59 % | -2,39 % | 30,86 % | 87,45 % |
| iShares Nikkei 225® | -0,05 % | -2,75 % | 60,15 % | 76,07 % |
| iShares S&P 500 | 0,94 % | 1,29 % | 23,99 % | 70,01 % |
Comments by Maxi_Scalibusa for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
(Vom Mitglied beendet)